In Q2 2024, Commodore Capital held 30 positions worth $1.2B. They initiated 3 new positions and exited 22. Their largest holding was NUVL ($112.9M). Portfolio value grew +0.9% versus the prior quarter.
Frequently asked questions
What stocks did Commodore Capital own in Q2 2024?
Commodore Capital held 30 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include NUVL, XENE, PCVX, ELVN, VERA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Commodore Capital's portfolio worth in Q2 2024?
Commodore Capital's tracked biotech portfolio was worth $1.2B across 30 positions, with total assets under management of approximately $1.5B. Portfolio values are based on 13F filings with the SEC.
What did Commodore Capital buy in Q2 2024?
Commodore Capital initiated 3 new positions in Q2 2024, including ALKS, PCSC, AVTX. They also increased 13 existing positions.
What did Commodore Capital sell in Q2 2024?
Commodore Capital fully exited 22 positions in Q2 2024, including RXDX, RZLT, ACET, DBVTF, ENGNW and 17 more. They also trimmed 4 existing positions.
Is Commodore Capital a biotech fund?
Healthcare-focused investment firm co-founded by Egen Atkinson and Michael Kramarz. Takes concentrated positions in biotech and life sciences companies, combining deep scientific analysis with active portfolio management.
Want AI analysis, insider signals, and catalyst overlays for Commodore Capital?
View latest Commodore Capitalportfolio →